WallStSmart

AngioDynamics Inc (ANGO)vsMerck & Company Inc (MRK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 20692% more annual revenue ($66.57B vs $320.17M). MRK leads profitability with a 4.8% profit margin vs -11.5%. ANGO appears more attractively valued with a PEG of 1.41. ANGO earns a higher WallStSmart Score of 40/100 (D).

ANGO

Hold

40

out of 100

Grade: D

Growth: 4.0Profit: 2.0Value: 7.0Quality: 4.8
Piotroski: 3/9Altman Z: -0.06

MRK

Hold

36

out of 100

Grade: F

Growth: 4.0Profit: 4.5Value: 2.0Quality: 5.0
Piotroski: 3/9Altman Z: 2.27
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ANGOUndervalued (+38.4%)

Margin of Safety

+38.4%

Fair Value

$18.45

Current Price

$15.27

$3.18 discount

UndervaluedFair: $18.45Overvalued
MRKSignificantly Overvalued (-73.7%)

Margin of Safety

-73.7%

Fair Value

$82.84

Current Price

$144.85

$62.01 premium

UndervaluedFair: $82.84Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ANGO0 strengths · Avg: 0/10

No standout strengths identified

MRK2 strengths · Avg: 9.0/10
Market CapQuality
$355.10B10/10

Mega-cap, among the largest globally

Free Cash FlowQuality
$4.48B8/10

Generating 4.5B in free cash flow

Areas to Watch

ANGO4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$631.15M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-21.5%2/10

ROE of -21.5% — below average capital efficiency

MRK4 concerns · Avg: 3.3/10
Price/BookValuation
8.5x4/10

Trading at 8.5x book value

Return on EquityProfitability
7.6%3/10

ROE of 7.6% — below average capital efficiency

Profit MarginProfitability
4.8%3/10

4.8% margin — thin

Debt/EquityHealth
1.293/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : ANGO

PEG of 1.41 suggests the stock is reasonably priced for its growth.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Free Cash Flow.

Bear Case : ANGO

The primary concerns for ANGO are EPS Growth, Market Cap, Piotroski F-Score.

Bear Case : MRK

The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.

Key Dynamics to Monitor

ANGO profiles as a turnaround stock while MRK is a value play — different risk/reward profiles.

ANGO carries more volatility with a beta of 0.33 — expect wider price swings.

ANGO is growing revenue faster at 8.0% — sustainability is the question.

MRK generates stronger free cash flow (4.5B), providing more financial flexibility.

Bottom Line

ANGO scores higher overall (40/100 vs 36/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

AngioDynamics Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

AngioDynamics, Inc. designs, manufactures and sells various medical, surgical and diagnostic devices for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company is headquartered in Latham, New York.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?